Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

MedTech

Qiagen said that it is partnering with Freenome to develop next-generation sequencing-based companion diagnostics for immuno-oncology. Under the agreement the companies will pair Freenome's artificial intelligence genomics platform with various Qiagen molecular analysis platforms and co-market the technologies to pharmaceutical companies.

Read more ...

Devices move from detection to measurement, and then to overall perceptual awareness.

A generally good macro-economic environment
According to Yole Développement latest report Status of the MEMS Industry 2018, 2017 was a growth year for the global semiconductor industry. Earnings were driven by increasing memory prices, a boost from cryptocurrencies, increasing adoption of graphics processing units (GPUs) by data centers and cloud companies for artificial intelligence (AI) tasks, and the popularity of e-sports.

Read more ...

Medgadget was recently invited to attend the imecTechnology Forum conference in Antwerp, Belgium. Imec is a non-profit R&D innovation organization specializing in nanoelectronics and digital technologies. Like many digital hardware companies, imec saw a lot of potential in healthcare technologies and started researching them about 12 years ago.

Read more ...

CellMax Life, a cancer diagnostics firm enabling early cancer detection with affordable non-invasive blood tests, today announced it is commencing Zenith, a U.S. clinical study for its circulating tumor cell (CTC) blood test, which can transform the way colorectal cancer is detected, enabling diagnosis at its earliest, most treatable stages.

Read more ...

ERS Genomics said that it has licensed its CRISPR-Cas9 genome editing patents to the NMI Natural and Medical Sciences Institute at the University of Tübingen and its affiliate NMI TT Pharmaservices. Under the terms of the non-exclusive licensing deal, NMI and NMI TT will gain access to the ERS patents in order to use them to expand their own custom cell-based research service offerings. Financial details of the agreement were not disclosed.

Read more ...

ERS Genomics said that it has licensed its CRISPR-Cas9 genome editing patents to the NMI Natural and Medical Sciences Institute at the University of Tübingen and its affiliate NMI TT Pharmaservices. Under the terms of the non-exclusive licensing deal, NMI and NMI TT will gain access to the ERS patents in order to use them to expand their own custom cell-based research service offerings. Financial details of the agreement were not disclosed.

Read more ...

Upcoming Events


> BIOtech Japan 2018
(June 27 - June 29, Tokyo, Japan)

Presentation

Point of Need Testing & Liquid Biopsy Technology and Market Overview:Challenges, market trends and new solutions
Discover the presentation held by Asma Siari at LOAC Europe 2018, on June 5, 2018, in Rotter...
BioMEMS, the next big thing for MEMS players ?
Discover the presentation held by Sébastien Clerc at MEMS & Sensors Executive Congress, in ...
Status of the Microfluidics Industry
Discover the presentation held by Sébastien Clerc at Sensor China Conference of September 1...

Access to all our presentations